Trial · NCT01678794

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

NCT01678794, Phase 1, Phase 2, Completed, Mayo Clinic; results first posted 2021-11-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function. Trials, record NCT01678794. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01678794

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
NCT number: NCT01678794
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 33 participants, actual
Lead sponsor: Mayo Clinic
Conditions: Cardiorenal Syndrome (CRS)
Interventions: Candesartan, Placebo
First posted: 2012-09-05
Last updated: 2021-11-18
Results first posted: 2021-11-18

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Glomerular Filtration Rate	baseline to 3 months	Glomerular Filtration Rate estimates how much blood passes through the glomeruli each minute. Glomeruli are the tiny filters in the kidneys that filter waste from the blood. Measured as ml/min/1.73 m2
Primary	Change in Urinary Sodium Excretion	baseline to 3 months	Urinary sodium excretion correlates with elevated blood pressure in subjects at low cardiovascular risk. The body continually monitors blood volume and sodium concentration. When either becomes too high, sensors in the heart, blood vessels, and kidneys detect the increases and stimulate the kidneys to increase sodium excretion, thus returning blood volume to normal. Measured as mEq/min

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Glomerular Filtration Rate	baseline to 3 months		ml/min/1.73 m2	MEDIAN
PRIMARY	Change in Urinary Sodium Excretion	baseline to 3 months		mEq/min	MEDIAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Glomerular Filtration Rate	Candesartan	-5	Inter-Quartile Range -14.5 to 3.5	ml/min/1.73 m2
Change in Glomerular Filtration Rate	Placebo	1.00	Inter-Quartile Range -8.00 to 6.00	ml/min/1.73 m2
Change in Urinary Sodium Excretion	Candesartan	-8.50	Inter-Quartile Range -30.50 to 48.50	mEq/min
Change in Urinary Sodium Excretion	Placebo	10.00	Inter-Quartile Range -53.00 to 66.00	mEq/min

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Candesartan	16
Overall Study	STARTED	Placebo	17
Overall Study	COMPLETED	Candesartan	16
Overall Study	COMPLETED	Placebo	17
Overall Study	NOT COMPLETED	Candesartan	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Urinary Tract Infection	Renal and urinary disorders	Candesartan	0	16	0
other	Urinary Tract Infection	Renal and urinary disorders	Placebo	1	17	1
other	Chest tightness	Respiratory, thoracic and mediastinal disorders	Candesartan	0	16	0
other	Chest tightness	Respiratory, thoracic and mediastinal disorders	Placebo	1	17	1
other	Increased plasma creatinine	Investigations	Candesartan	1	16	1
other	Increased plasma creatinine	Investigations	Placebo	1	17	1
other	Hyperkalemia	Metabolism and nutrition disorders	Candesartan	3	16	3
other	Hyperkalemia	Metabolism and nutrition disorders	Placebo	0	17	0
other	Joint pain	Musculoskeletal and connective tissue disorders	Candesartan	0	16	0
other	Joint pain	Musculoskeletal and connective tissue disorders	Placebo	1	17	1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Candesartan	0	16
Total, all-cause mortality	Placebo	0	17
Total, other adverse events	Candesartan	5	16
Total, other adverse events	Placebo	5	17
Total, serious adverse events	Candesartan	0	16
Total, serious adverse events	Placebo	0	17

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01HL084155	Human Cardiorenal Syndrome	CHEN, HORNG H	MAYO CLINIC ROCHESTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2009 to 2025

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Candesartan vs Placebo: deaths from any cause	Trial comparisons
Candesartan vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01678794

GET https://conductscience.org/api/trials/v1/NCT01678794/registered

API reference For AI assistants